ESMO 2023 | Adjuvant treatment guidelines in post-menopausal women with breast cancer

Patrick Neven, MD, University Hospitals Leuven, Leuven, Belgium, provides an overview of management strategies for post-menopausal patients with ER+/HER2- breast cancer. In a meta-analysis, tamoxifen with an aromatase significantly improved survival, and additional clinical trials are being conduced to assess their efficacy in patients 5-10 years post-diagnosis. Prof. Neven additionally highlights Clinical Treatment Score at 5 years (CTS5) as a prognostic tool and the potential benefits of selective estrogen receptor downregulators (SERDs). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.